Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test 2026 - Free AOCNP Practice Questions and Study Guide

The correct choice for managing bone pain in cancer patients is the class of medications known as bisphosphonates or RANKL inhibitors. These medications specifically target the bone microenvironment and can effectively reduce pain associated with bone metastases. Bisphosphonates, such as zoledronic acid or pamidronate, work by inhibiting osteoclast activity, which decreases bone resorption, helps stabilize bone structure, and reduces the release of pain-causing factors. RANKL inhibitors, like denosumab, also act to prevent osteoclast formation and function, further decreasing bone pain linked to malignancies.

Both bisphosphonates and RANKL inhibitors not only help manage symptoms but can also have a beneficial effect on the progression of skeletal-related events in patients with bone metastases, making them a valuable option in palliative care for cancer patients.

Other options, while they may have roles in pain management, do not specifically address the underlying processes causing bone pain from malignancies. Opioids are often used for general pain management, including severe pain, but they do not directly target the bone process. NSAIDs may help with mild pain but lack the targeted action against bone remodeling issues in cancer. Corticosteroids can